2025
A neoantigen vaccine generates antitumour immunity in renal cell carcinoma
Braun D, Moranzoni G, Chea V, McGregor B, Blass E, Tu C, Vanasse A, Forman C, Forman J, Afeyan A, Schindler N, Liu Y, Li S, Southard J, Chang S, Hirsch M, LeBoeuf N, Olive O, Mehndiratta A, Greenslade H, Shetty K, Klaeger S, Sarkizova S, Pedersen C, Mossanen M, Carulli I, Tarren A, Duke-Cohan J, Howard A, Iorgulescu J, Shim B, Simon J, Signoretti S, Aster J, Elagina L, Carr S, Leshchiner I, Getz G, Gabriel S, Hacohen N, Olsen L, Oliveira G, Neuberg D, Livak K, Shukla S, Fritsch E, Wu C, Keskin D, Ott P, Choueiri T. A neoantigen vaccine generates antitumour immunity in renal cell carcinoma. Nature 2025, 639: 474-482. PMID: 39910301, PMCID: PMC11903305, DOI: 10.1038/s41586-024-08507-5.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntigens, NeoplasmCancer VaccinesCarcinoma, Renal CellClass I Phosphatidylinositol 3-KinasesDNA-Binding ProteinsFemaleHumansIpilimumabKidney NeoplasmsMaleMiddle AgedMutationPrecision MedicineT-LymphocytesTranscription FactorsTumor Suppressor ProteinsUbiquitin ThiolesteraseVon Hippel-Lindau Tumor Suppressor ProteinConceptsPersonalized cancer vaccinesRenal cell carcinomaDriver mutationsAntitumour immunityCell carcinomaI trialResected clear cell renal cell carcinomaImmune responseT cell immune responsesClear cell renal cell carcinomaHigh-risk RCCDose-limiting toxicityLow mutational burdenCell renal cell carcinomaEffective adjuvant therapyPhase I trialT cell reactivityAbsence of recurrenceCirculating immune responsesCell immune responseAutologous tumorNeoantigen vaccinesCancer vaccinesAdjuvant therapyMutational burdenQuality of gastrointestinal surgical oncology care according to insurance status
Butensky S, Kerekes D, Bakkila B, Billingsley K, Ahuja N, Johnson C, Khan S. Quality of gastrointestinal surgical oncology care according to insurance status. Journal Of Gastrointestinal Surgery 2025, 29: 101961. PMID: 39800081, DOI: 10.1016/j.gassur.2025.101961.Peer-Reviewed Original ResearchConceptsMedicare-insured patientsNational Cancer DatabaseAdequate lymphadenectomyNegative marginsCancer DatabaseRetrospective study of adult patientsStudy of adult patientsSurvival analysisInsurance statusReceipt of lymphadenectomyCurative-intent resectionGastrointestinal (GI) cancersIncreased risk of deathMultivariate survival analysisAdequacy of lymphadenectomyCox proportional hazards modelsRisk of deathProportional hazards modelResection marginsSurgical oncology careAdjuvant therapyRetrospective studyAdult patientsBiliary organismsLymphadenectomy
2024
The evolving landscape of adjuvant therapy in T1-T2N0 resected non-small cell lung cancer: a narrative review
Zolfaghari E, Dhanasopon A, Woodard G. The evolving landscape of adjuvant therapy in T1-T2N0 resected non-small cell lung cancer: a narrative review. Journal Of Thoracic Disease 2024, 0: 0-0. PMID: 39831209, PMCID: PMC11740046, DOI: 10.21037/jtd-24-245.Peer-Reviewed Original ResearchNon-small cell lung cancerEpidermal growth factor receptorEarly-stage non-small cell lung cancerAnaplastic lymphoma kinaseAdjuvant therapyCell lung cancerEarly-stage patientsSurgical resectionOverall survivalAdjuvant chemotherapyLung cancerSurvival benefit of adjuvant therapyAdjuvant platinum-based chemotherapyBenefit of adjuvant therapyHigh-risk pathologic featuresStage IB tumorsNational Clinical Trials RegistryPlatinum-based chemotherapyHigh-risk featuresCirculating tumor DNALandscape of adjuvant therapyLung cancer recurrenceGrowth factor receptorClinical Trials RegistryAdjuvant osimertinibLiving on the Edge: Role of Adjuvant Therapy After Resection of Primary Lung Cancer Within 2 Millimeters of a T-Stage Cutoff
Udelsman B, Bedrosian C, Kawaguchi E, Ding L, Wallace W, Rosenberg G, Harano T, Wightman S, Atay S, Kim A, Woodard G. Living on the Edge: Role of Adjuvant Therapy After Resection of Primary Lung Cancer Within 2 Millimeters of a T-Stage Cutoff. Journal Of Thoracic And Cardiovascular Surgery 2024 PMID: 39521371, DOI: 10.1016/j.jtcvs.2024.10.053.Peer-Reviewed Original ResearchNon-small cell lung cancerSystemic therapyOverall survivalT stageTumor sizeResected non-small cell lung cancerLung cancerNational Cancer Database of patientsResection of primary lung cancerOutcomes of systemic therapyPathologic tumor sizeNational Cancer DatabaseAdjuvant therapy useUse of systemic therapyPrimary lung cancerResection of tumorsCell lung cancerAssociated with decreased ratesDatabase of patientsRetrospective cohort studyTumor size distributionDownstaged patientsNodal involvementUnder-stagingAdjuvant therapyPrimary Treatment of Eyelid Conjunctival Melanoma with Immunotherapy: A Case Report
Weiss M, Perzia B, Sinard J, Tran T, Maeng M. Primary Treatment of Eyelid Conjunctival Melanoma with Immunotherapy: A Case Report. Ophthalmic Plastic And Reconstructive Surgery 2024, 41: e12-e15. PMID: 39240220, DOI: 10.1097/iop.0000000000002776.Peer-Reviewed Original ResearchConjunctival melanomaImmune checkpoint inhibitor regimenCombination of ipilimumabFirst-line combinationImmune checkpoint inhibitorsMonths of treatmentSystemic adverse effectsCutaneous melanoma treatmentHigher recurrence rateCheckpoint inhibitorsMucosal melanomaAdjuvant therapyDisease resolutionRecurrence rateLocal surgeryMelanoma treatmentFrequent metastasisCase reportPrimary treatmentMelanomaClinical approachIpilimumabNivolumabConjunctivalAdverse effectsWound Healing Society 2023 update on guidelines for arterial ulcers
Federman D, Dardik A, Shapshak D, Ueno C, Masterson L, Hopf H, Abdullah N, Junkins S, Mostow E. Wound Healing Society 2023 update on guidelines for arterial ulcers. Wound Repair And Regeneration 2024, 32: 619-629. PMID: 39021056, DOI: 10.1111/wrr.13204.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsRelevant new findingsLevel of evidenceEmergency medicine physiciansWound bed preparationAdjuvant therapySociety guidelinesWound Healing SocietyMedicine physiciansVascular surgeonsPlastic surgeonsInfection controlLong-term maintenanceBed preparationArterial ulcersUlcer managementWound healingArterial insufficiency ulcersSurgeonsWoundAdvisory PanelUlcersGuidelinesSurgeryHealing SocietyTherapyAdjuvant imatinib in high‐risk resected gastrointestinal stromal tumors: Merely delaying the inevitable?
Sutton T, Billingsley K, Johnson A, Corless C, Blanke C, Heinrich M, Mayo S. Adjuvant imatinib in high‐risk resected gastrointestinal stromal tumors: Merely delaying the inevitable? Journal Of Surgical Oncology 2024, 130: 40-46. PMID: 38924626, DOI: 10.1002/jso.27654.Peer-Reviewed Original ResearchHigh-risk gastrointestinal stromal tumorsRecurrence-free survivalGastrointestinal stromal tumorsResected gastrointestinal stromal tumorsAdjuvant imatinibOverall survivalStromal tumorsAdjuvant therapyDuration of adjuvant imatinibBenefit of adjuvant therapyMonths of postsurgical follow-upMultivariate Cox proportional hazards modelPostsurgical follow-upKaplan-Meier analysisCox proportional hazards modelsProportional hazards modelRadiographic recurrenceImatinib resistanceReviewed patientsFollow-upImatinibOncological treatmentCytocidal effectCancer CenterPatientsCorrelating Predicted Adjuvant Therapy Benefit and Risk of Recurrence Between Breast Cancer Index (BCI) and the 21-Gene Oncotype DX Recurrence Score (RS)
Casasanta N, Patel R, Raymond S, Kier M, Blanter J, Sohval S, Hovstadius M, Wu C, Zimmerman B, Cascetta K, Bagiella E, Tiersten A. Correlating Predicted Adjuvant Therapy Benefit and Risk of Recurrence Between Breast Cancer Index (BCI) and the 21-Gene Oncotype DX Recurrence Score (RS). Clinical Breast Cancer 2024, 24: 585-596. PMID: 38971641, DOI: 10.1016/j.clbc.2024.06.005.Peer-Reviewed Original ResearchBreast Cancer IndexEarly-stage breast cancerOncotype DX RSAssociated with discordanceOncotype DX recurrence scoreAdjuvant therapy benefitReview of womenOncotype DXRecurrence scoreRecurrence riskEndocrine therapyCancer indexRetrospective chart review of womenChart review of womenRetrospective review of womenRisk of distant recurrenceTherapy benefitRisk of recurrenceRetrospective chart reviewRegression modelsUnivariate logistic regression modelLogistic regression modelsPrediction scoreDistant recurrenceAdjuvant therapyPhage Therapy for Respiratory Infections: Opportunities and Challenges
Khosravi A, Chen Q, Echterhof A, Koff J, Bollyky P. Phage Therapy for Respiratory Infections: Opportunities and Challenges. Lung 2024, 202: 223-232. PMID: 38772946, PMCID: PMC11570333, DOI: 10.1007/s00408-024-00700-7.Peer-Reviewed Original ResearchChronic lung infectionLung infectionRespiratory infectionsAntimicrobial resistancePhage therapyClinical trialsPhage therapy clinical trialsProgressive respiratory failureChronic respiratory infectionsPersonalized phage therapyAntimicrobial resistant infectionsPost-antibiotic eraPotential of phagesSalvage therapyAdjuvant therapyRespiratory failureDisease resolutionChronic respiratory diseasesTreatment efficacyTherapyTherapeutic potentialIncreased mortalityInfectionNovel antibioticsPhageUsing Computed Tomography-Based Three-dimensional Modeling and Computer Navigation for Minimally Invasive Core Decompression and Adjuvant Orthobiologic Therapy of Femoral Head Avascular Necrosis
Feizi A, Bell C, Roytman G, Park N, Wang A, Tommasini S, Wiznia D. Using Computed Tomography-Based Three-dimensional Modeling and Computer Navigation for Minimally Invasive Core Decompression and Adjuvant Orthobiologic Therapy of Femoral Head Avascular Necrosis. Arthroplasty Today 2024, 26: 101337. PMID: 38497084, PMCID: PMC10940782, DOI: 10.1016/j.artd.2024.101337.Peer-Reviewed Original ResearchFemoral head avascular necrosisAvascular necrosisSurgical techniqueCore decompressionBone marrow aspirate concentrateDelay disease progressionOutcome of core decompressionAdjuvant therapyCellular therapyAspirate concentrateDisease progressionFemoral head collapseImprove outcomesLesionsDebilitating conditionTherapyComputer navigationNecrosisDecompressionHead collapseThree-dimensional modelFemoral headInfigratinib versus placebo in patients with resected urothelial cancer (UC) bearing FGFR3 mutation or fusion: Primary DFS analysis from the phase 3, randomized PROOF302 study.
Pal S, Grivas P, Gupta S, Valderrama B, Rodriguez-Vida A, Roghmann F, Sevillano E, Matin S, Loriot Y, Sridhar S, Sonpavde G, Fleming M, Lerner S, Bellmunt J, Master V, Tripathi A, Davis K, Van Veenhuyzen D, Weng R, Daneshmand S. Infigratinib versus placebo in patients with resected urothelial cancer (UC) bearing FGFR3 mutation or fusion: Primary DFS analysis from the phase 3, randomized PROOF302 study. Journal Of Clinical Oncology 2024, 42: 629-629. DOI: 10.1200/jco.2024.42.4_suppl.629.Peer-Reviewed Original ResearchDisease-free survivalMetastasis-free survivalOverall survivalUrothelial cancerFibroblast growth factor 3FGFR3 alterationsAdjuvant therapyAdverse eventsInvestigator-assessed disease-free survivalMulticenter phase III clinical trialAssessed disease-free survivalPhase III clinical trialsLower tract UCUpper tract UCDays of randomizationFatal adverse eventsIII clinical trialsPrecision oncology trialsDFS analysisMetastatic settingOral infigratinibRadical surgeryDisease recurrenceFrequent gradeInvasive UC
2023
Pathological response in mucinous carcinoma of breast after neoadjuvant therapy - a multi-institutional study
Zhan H, Fineberg S, Podany P, Zeng J, Wang Y, Harigopal M, Singh K. Pathological response in mucinous carcinoma of breast after neoadjuvant therapy - a multi-institutional study. Human Pathology 2023, 142: 15-19. PMID: 37972873, DOI: 10.1016/j.humpath.2023.10.002.Peer-Reviewed Original ResearchConceptsNeoadjuvant endocrine therapyResidual tumour cellularityNeoadjuvant chemotherapyNeoadjuvant therapyMucinous carcinomaPathologic responseEndocrine therapyPathological responseMucin poolsBreast cancerEstrogen receptorTumor cellularityAcellular mucin poolsFavorable histologic subtypePreoperative adjuvant therapyRetrospective cohort studyComplete pathologic responseInvasive breast cancerNET groupMulti-institutional studyNeoadjuvant HER2Adjuvant therapyMC patientsCohort studyPathologic reviewPrognostic impact of reduced HER2 protein expression in post-neoadjuvant therapy resection specimens: A single institution experience and review of the literature
Mogica J, Tang H, Liang Y, Zhong M, Hui P, Harigopal M, Krishnamurti U, Fischbach N, Zhan H. Prognostic impact of reduced HER2 protein expression in post-neoadjuvant therapy resection specimens: A single institution experience and review of the literature. The Breast 2023, 72: 103586. PMID: 37812963, PMCID: PMC10568274, DOI: 10.1016/j.breast.2023.103586.Peer-Reviewed Original ResearchConceptsHER2 IHC 3Human epidermal growth factor receptor 2Kaplan-Meier survival analysisHER2-IHC expressionPathologic complete responseResidual diseaseIHC 3Breast cancerIHC expressionSurvival analysisSuperior disease-free survivalEpidermal growth factor receptor 2Intensive adjuvant therapyPost-therapy surveillanceYale Cancer CenterDisease-free survivalGrowth factor receptor 2Recurrence-free survivalSingle institution experienceLow recurrence rateFactor receptor 2HER2 protein expressionAdjuvant trialsNeoadjuvant treatmentAdjuvant therapyCorrelation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial)
Hennessy M, Leal J, Huang C, Solnes L, Denbow R, Abramson V, Carey L, Liu M, Rimawi M, Specht J, Storniolo A, Valero V, Vaklavas C, Winer E, Krop I, Wolff A, Cimino-Mathews A, Wahl R, Stearns V, Connolly R. Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial). Journal Of Nuclear Medicine 2023, 64: jnumed.123.265853. PMID: 37652539, DOI: 10.2967/jnumed.123.265853.Peer-Reviewed Original ResearchConceptsF-FDG PET/CTHER2-positive breast cancerRecurrence-free survivalPET/CTPathologic complete responseOverall survivalBreast cancerOperable HER2-positive breast cancerHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Growth factor receptor 2Kaplan-Meier methodStatistical significanceLean body massFactor receptor 2Imaging-based biomarkersCorrelation of SUVHER2 therapyNeoadjuvant trastuzumabNeoadjuvant therapyAdjuvant therapyComplete responsePhysician's discretionOS outcomesCox regressionDichloroacetate as a novel pharmaceutical treatment for cancer-related fatigue in melanoma
Zhang X, Lee W, Leitner B, Zhu W, Fosam A, Li Z, Gaspar R, Halberstam A, Robles B, Rabinowitz J, Perry R. Dichloroacetate as a novel pharmaceutical treatment for cancer-related fatigue in melanoma. AJP Endocrinology And Metabolism 2023, 325: e363-e375. PMID: 37646579, PMCID: PMC10642987, DOI: 10.1152/ajpendo.00105.2023.Peer-Reviewed Original ResearchConceptsCancer-related fatigueNovel pharmaceutical treatmentsPhysical functionPharmaceutical treatmentTumor growthCancer treatmentStandard cancer treatmentTumor-bearing miceLate-stage tumorsEffective pharmaceutical treatmentMurine cancer modelsNew metabolic targetsMultiple cancer typesAdjuvant therapyCommon complicationPatients' qualitySymptom managementClinical trialsMurine modelPotential therapyPharmaceutical therapySmall molecule inhibitorsCancer modelDCA treatmentLactate concentrationNeoadjuvant Immunotherapy in Early, Triple-Negative Breast Cancers: Catching Up with the Rest
Kim L, Coman M, Pusztai L, Park T. Neoadjuvant Immunotherapy in Early, Triple-Negative Breast Cancers: Catching Up with the Rest. Annals Of Surgical Oncology 2023, 30: 6441-6449. PMID: 37349612, DOI: 10.1245/s10434-023-13714-x.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerTumor mutational burdenBreast cancerAdjuvant therapyPathological complete response rateImmune checkpoint modulationComplete response rateExcellent clinical outcomesCombination immunochemotherapyNeoadjuvant immunotherapyNeoadjuvant settingNeoadjuvant chemotherapyOverall survivalPD-L1Checkpoint modulationClinical outcomesMajor trialsMutational burdenResponse rateCancer typesCancerTherapyBiomarkersOutcomesExciting advancesPrognostic value of absolute lymphocyte count in oral cavity squamous cell carcinoma
Shah R, Liu C, Shah H, Judson B. Prognostic value of absolute lymphocyte count in oral cavity squamous cell carcinoma. Laryngoscope Investigative Otolaryngology 2023, 8: 870-875. PMID: 37621277, PMCID: PMC10446262, DOI: 10.1002/lio2.1094.Peer-Reviewed Original ResearchOral cavity squamous cell carcinomaAbsolute lymphocyte countOral cavity cancerSquamous cell carcinomaRate of deathLikelihood of recurrenceLymphocyte countPrognostic valueCell carcinomaCancer patientsPreoperative absolute lymphocyte countPretreatment absolute lymphocyte countLate-stage cancer patientsRetrospective chart reviewAmerican Joint CommitteeDay of surgeryEarly-stage cancer patientsTumor registry dataAdjuvant therapyOutcome patientsChart reviewPrimary outcomeALC valuesPositive marginsPrognostic indicatorDerivation, Validation, and Clinical Relevance of a Pediatric Sepsis Phenotype With Persistent Hypoxemia, Encephalopathy, and Shock*
Sanchez-Pinto L, Bennett T, Stroup E, Luo Y, Atreya M, Bubeck Wardenburg J, Chong G, Geva A, Faustino E, Farris R, Hall M, Rogerson C, Shah S, Weiss S, Khemani R. Derivation, Validation, and Clinical Relevance of a Pediatric Sepsis Phenotype With Persistent Hypoxemia, Encephalopathy, and Shock*. Pediatric Critical Care Medicine 2023, 24: 795-806. PMID: 37272946, PMCID: PMC10540758, DOI: 10.1097/pcc.0000000000003292.Peer-Reviewed Original ResearchMultiple organ dysfunction syndromeSepsis-associated multiple organ dysfunction syndromePersistent hypoxemiaAdjuvant therapySepsis phenotypesSevere pediatric acute respiratory distress syndromePediatric acute respiratory distress syndromeMulticenter observational cohort studyAcute respiratory distress syndromePropensity score-matched analysisCommon adjuvant therapyHeterogeneity of sepsisOrgan dysfunction syndromeObservational cohort studyRespiratory distress syndromeHospital mortalityCohort studyDysfunction syndromeSystemic inflammationDistress syndromeOrgan dysfunctionSeptic shockClinical syndromeCommon therapyClinical relevanceHRD signature and HRD genomic landscape of tumors from 896 patients with early-stage breast cancer (BC).
Jeon J, Chen K, Madison R, Schrock A, Sokol E, Levy M, Oxnard G, Huang R, Pusztai L. HRD signature and HRD genomic landscape of tumors from 896 patients with early-stage breast cancer (BC). Journal Of Clinical Oncology 2023, 41: 539-539. DOI: 10.1200/jco.2023.41.16_suppl.539.Peer-Reviewed Original ResearchEarly-stage breast cancerPrimary breast cancerEarly breast cancerBreast cancerStage IHR-/HER2HRR deficiencyPALB2 mutationsEarly-stage primary breast cancerPARP inhibitorsStage IV diseaseHormone receptor statusMonths of diagnosisPositive breast cancerHomologous recombination repairComprehensive genomic profilingHRD signaturesClinical trial dataHigh rateSEER studySomatic BRCAAdjuvant therapyAdvanced diseaseReceptor statusBC subtypesDecreased HER2 expression in residual disease following neoadjuvant therapy in patients with HER2-positive breast cancer.
Paredes Mogica J, Tang H, Fischbach N, Zhan H. Decreased HER2 expression in residual disease following neoadjuvant therapy in patients with HER2-positive breast cancer. Journal Of Clinical Oncology 2023, 41: e12621-e12621. DOI: 10.1200/jco.2023.41.16_suppl.e12621.Peer-Reviewed Original ResearchNeo-adjuvant therapyKaplan-Meier survival analysisHER2 IHC 3Pathologic complete responseResidual diseaseBreast cancerHER2 expressionAdjuvant therapyNeoadjuvant therapyEpidermal growth factor receptor 2 overexpressionHuman epidermal growth factor receptor 2 (HER2) overexpressionSurvival analysisHER2-positive breast cancerAggressive adjuvant therapyHER2-IHC expressionPost-therapy surveillanceResidual invasive tumorTrastuzumab/pertuzumabYale Cancer CenterRecurrence-free survivalBreast cancer outcomesAdo-trastuzumab emtansineLow recurrence rateStandard of careAssociation of pre
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply